Biogen Inc. (BIIB) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Drug Manufacturers - General
Biogen Inc. (BIIB) Profile & Business Summary
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Key Information
| Ticker | BIIB |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.biogen.com |
Market Trend Overview for BIIB
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-08-28 (ET)
As of 2026-08-28, BIIB is starting to move higher. Over the longer term, the trend remains bullish.
BIIB last closed at 218.50. The price is about 1.0 ATR above its recent average price (212.65), and the market is currently in an early upward move. Price at 218.50 is holding above minor support near 201.00. If price continues higher, it may face light resistance around 218.59. View Support & Resistance from Options
The trend is still positive, but signs of slowing momentum suggest growing two-sided risk.
Trend score: 80 out of 100. Overall alignment is strong. The market is currently in an early-stage uptrend. Trend signals are well aligned across timeframes, suggesting a stable and consistent trend.
A key downside risk boundary is near 199.78. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-07-28, reflecting a technical shift toward positive directional alignment.
[2026-07-22] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
The model sees a credible bullish edge, with 68.6% upside probability, strong signal alignment, and reward/risk that remains meaningfully favorable.
Up probability is 68.6%, with predictability at 65% and signal agreement at 89%. Reversal risk is 11%, while reward/risk stands at 0.40. That suggests the directional case is supported by broad confirmation and still retains usable quality. At the same time, recent price behavior has shown failed reversal memory.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 27 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-08-28. The current price is 218.50, 4.33% above the estimated average cost of 209.43. An estimated 88.2% of recent positioning is below the current price, while 11.5% is above it. The peak-density price is 207.20. The largest concentrated cost region is 203.75 to 210.25 and contains 47.0% of the estimated distribution. The nearest region below the current price is 217.75 to 218.05. The nearest region above the current price is 220.85 to 221.65.
Short Interest & Covering Risk for BIIB
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 44%)
Structure Analysis
BIIB Short positioning looks normal. Current days to cover is 4.7 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 24/100, DTC percentile 86%) while price maintains a mild upward bias (20D return 7.7%). Positioning is historically elevated, although price and liquidity conditions do not yet confirm structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. Price action is compressing (range is tightening), which can make breaks more sensitive. Price is consolidating near highs with a weak upward bias; surface strength may mask a more fragile structure. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. High-level consolidation and compression suggest a fragile upside structure. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-07-31 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.